Table 2 Population characteristics unmatched and matched study group.
From: Asthma and COPD management of patients with intellectual disabilities in general practice
Characteristics unmatched study group | Persons intellectual disabilities and asthma (n = 157) n (%) | Persons asthma no intellectual disabilities (n = 15,319) n (%) | Persons intellectual disabilities and COPD (n = 71) n (%) | Persons COPD no intellectual disabilities (n = 9058) n (%) |
|---|---|---|---|---|
Sex | ||||
Male | 69 (43.9%) | 6394 (41.7%) | 35 (49.3%) | 4997 (55.2%) |
Female Unknown | 88 (56.1%) | 8924 (58.3%) 1 (0.0%) | 36 (50.7%) | 4061 (44.8%) |
Age (years) | Statistical significance*** (comparison patients with and without intellectual disabilities in each age group) | Statistical significance*** (comparison patients with and without intellectual disabilities in each age group) | ||
18–34 | 80 (51.0%) | 5139 (33.5%) | 2 (2.8%) | 50 (0.6%) |
35–49 | 53 (33.8%) | 4719 (30.8%) | 19 (26.8%) | 892 (9.8%) |
50–64 | 20 (12.7%) | 3561 (23.2%) | 36 (50.7%) | 3714 (41.0%) |
≥65 | 4 (2.5%) | 1900 (12.4%) | 14 (19.7%) | 4402 (48.6%) |
Characteristics matched study group | Persons intellectual disabilities and asthma (n = 156) n (%) | Matched controls asthma no intellectual disabilities (n = 312) n (%) | Persons intellectual disabilities and COPD (n = 68) n (%) | Matched controls COPD no intellectual disabilities (n = 133) n (%) |
|---|---|---|---|---|
Sex | ||||
Male | 69 (44.2%) | 138 (44.2%) | 34 (50.0%) | 66 (49.6%) |
Female | 87 (55.8%) | 174 (55.8%) | 34 (50.0%) | 67 (50.4%) |
Age (years) | ||||
18–34 | 80 (51.3%) | 160 (51.3%) | 0 | 0 |
35–49 | 52 (33.3%) | 104 (33.3%) | 18 (26.5%) | 33 (24.8%) |
50–64 | 20 (12.8%) | 40 (12.8%) | 36 (52.9%) | 72 (54.1%) |
≥65 | 4 (2.6%) | 8 (2.6%) | 14 (20.6%) | 28 (21.1%) |
Smoking status | Statistical significance*** (comparison patients with and without intellectual disabilities in each category) | Statistical significance*** (comparison patients with and without intellectual disabilities in each category) | ||
Yes | 38 (45.2%) | 32 (22.1%) | 36 (76.6%) | 54 (51.4%) |
Never | 25 (29.8%) | 71 (49.0%) | 2 (4.3%) | 8 (7.6%) |
Stopped | 21 (25.0%) | 42 (29.0%) | 9 (19.1%) | 43 (41.0%) |
Missing information | 72 | 167 | 21 | 28 |
Year of diagnosis | ||||
<2010 | 93 (59.6%) | 186 (59.6%) | 26 (38.2%) | 50 (37.6%) |
2010–2019 | 63 (40.4%) | 126 (40.4%) | 42 (61.8%) | 83 (62.4%) |
Years of follow-up during the study period | ||||
<1 year | 10 (6.4%) | 18 (5.8%) | 8 (11.8%) | 19 (14.3%) |
1–4 years | 46 (29.5%) | 86 (27.6%) | 23 (33.8%) | 45 (33.8%) |
5–9 years | 34 (21.8%) | 66 (21.2%) | 24 (35.3%) | 39 (29.3%) |
10 years | 66 (42.3%) | 142 (45.5%) | 13 (19.1%) | 30 (22.6%) |
Comorbidity | ||||
Obesity | 58 (53.2%)* | 64 (39.5%)* | 17 (32.7%) | 26 (23.6%) |
Missing information | 47 | 150 | 16 | 23 |
Hypertension | 27 (17,3%) | 44 (14.1%) | 23 (33.8%) | 58 (43.6%) |
Ischaemic heart disease | 7 (4.5%) | 18 (5.8%) | 8 (11.8%) | 25 (18.8%) |
Heart failure | 2 (1.3%) | 4 (1.3%) | 4 (5.9%) | 17 (12.8%) |
Cerebrovascular accident | 3 (1.9%) | 4 (1.3%) | 6 (8.8%) | 9 (6.8%) |
Diabetes | 23 (14.7%)* | 26 (8.3%)* | 12 (17.6%) | 20 (15.0%) |
Anxiety/depression | 54 (34.6%)** | 68 (21.8%)** | 26 (38.2%) | 36 (27.1%) |
Osteoporosis | 3 (1.9%) | 6 (1.9%) | 5 (7.4%) | 17 (12.8%) |
Osteoarthritis | 11 (7.1%) | 24 (7.7%) | 12 (17.5%) | 28 (21.1%) |
